| scholarly article | Q13442814 |
| P356 | DOI | 10.1176/AJP.152.11.1652 |
| P8608 | Fatcat ID | release_pngmvtnlujfchd4bqr6rfmvev4 |
| P698 | PubMed publication ID | 7485630 |
| P50 | author | Joseph Biederman | Q6281524 |
| Stephen Faraone | Q7609174 | ||
| P2093 | author name string | Wilens T | |
| Mick E | |||
| Spencer TJ | |||
| Milberger S | |||
| P433 | issue | 11 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | attention deficit hyperactivity disorder | Q181923 |
| comorbidity | Q1414874 | ||
| attention | Q6501338 | ||
| P304 | page(s) | 1652-1658 | |
| P577 | publication date | 1995-11-01 | |
| P1433 | published in | American Journal of Psychiatry | Q1935368 |
| P1476 | title | Psychoactive substance use disorders in adults with attention deficit hyperactivity disorder (ADHD): effects of ADHD and psychiatric comorbidity | |
| P478 | volume | 152 |
| Q35957593 | A common genetic network underlies substance use disorders and disruptive or externalizing disorders |
| Q46861089 | A controlled trial of methylphenidate in adults with attention deficit/hyperactivity disorder and substance use disorders. |
| Q48410576 | A naturalistic study of the effects of pharmacotherapy on substance use disorders among ADHD adults |
| Q34481402 | A placebo-controlled trial of atomoxetine in marijuana-dependent individuals with attention deficit hyperactivity disorder |
| Q21129117 | A systematic review of global publication trends regarding long-term outcomes of ADHD |
| Q61443148 | ADGRL3 (LPHN3) variants predict substance use disorder |
| Q34268083 | ADHD as a risk factor for early onset and heightened adult problem severity of illicit substance use: an accelerated gateway model |
| Q48620426 | ADHD burden of illness in older adults: a life course perspective |
| Q51900305 | ADHD prevalence in adult outpatients with nonpsychotic psychiatric illnesses. |
| Q38209196 | ADHD treatment and pregnancy |
| Q37056071 | ADHD, substance use disorders, and psychostimulant treatment: current literature and treatment guidelines |
| Q36038893 | AOD use and attention deficit/hyperactivity disorder. |
| Q36311022 | Adult ADHD and substance abuse: diagnostic and treatment issues |
| Q93144102 | Adult ADHD: a controversial diagnosis? |
| Q37040031 | Age of Onset, Duration, and Type of Medication Therapy for Attention-Deficit/Hyperactivity Disorder and Substance Use During Adolescence: A Multi-Cohort National Study |
| Q36262529 | Alcohol, drugs, and attention-deficit/ hyperactivity disorder: a model for the study of addictions in youth |
| Q48119039 | Altered cingulate and amygdala response towards threat and safe cues in attention deficit hyperactivity disorder |
| Q35878684 | An Open Trial of Sustained Release Bupropion for Attention-Deficit/Hyperactivity Disorder in Adults with ADHD plus Substance Use Disorders. |
| Q48490895 | An Ultraconserved Brain-Specific Enhancer Within ADGRL3 (LPHN3) Underpins Attention-Deficit/Hyperactivity Disorder Susceptibility |
| Q44294433 | An epidemiological study of ADHD, substance use, and comorbid problems in incarcerated women in Sweden. |
| Q44932521 | An examination of the psychometric properties of the attention deficit scales for adults with outpatient substance abusers |
| Q34995011 | Assessment and management of attention-deficit hyperactivity disorder in adults. |
| Q37200559 | Association of the cannabinoid receptor gene (CNR1) with ADHD and post-traumatic stress disorder |
| Q36992386 | Associations between attention deficit hyperactivity disorder symptom domains and DSM-IV lifetime substance dependence |
| Q37024541 | Associations between maternal attention-deficit/hyperactivity disorder symptoms and parenting |
| Q38581725 | Atomoxetine treatment in adults with attention-deficit/hyperactivity disorder |
| Q38848602 | Attention Deficit Hyperactivity Disorder and adult mortality |
| Q38946354 | Attention Deficit Hyperactivity Disorder, Aggression, and Illicit Stimulant Use: Is This Self-Medication? |
| Q38569727 | Attention deficit hyperactivity disorder and substance misuse: an evaluation of causal hypotheses and treatment considerations. |
| Q43489389 | Attention deficit hyperactivity disorder in cocaine-dependent adults: a psychiatric comorbidity analysis |
| Q38920631 | Attention, reward, and inhibition: symptomatic features of ADHD and issues for offenders in the criminal justice system |
| Q22241431 | Attention-Deficit Hyperactivity Disorder in Girls |
| Q60636989 | Attention-deficit/hyperactivity disorder and lifetime cannabis use: genetic overlap and causality |
| Q35738078 | Attention-deficit/hyperactivity disorder and the substance use disorders: the nature of the relationship, subtypes at risk, and treatment issues |
| Q33911442 | Attention-deficit/hyperactivity disorder in adults: an overview |
| Q54965516 | Augmented Go/No-Go Task: Mouse Cursor Motion Measures Improve ADHD Symptom Assessment in Healthy College Students. |
| Q97528202 | Autistic Traits in Young Adults Who Gamble |
| Q40650415 | Bupropion treatment for cocaine abuse and adult attention-deficit/hyperactivity disorder |
| Q48345944 | Characteristics of ADHD among Omani schoolchildren using DSM-IV: descriptive study |
| Q37122991 | Childhood ADHD and conduct disorder as independent predictors of male alcohol dependence at age 40. |
| Q94502574 | Childhood Adversity and Dimensional Variations in Adult Sustained Attention |
| Q37522428 | Childhood and current ADHD symptom dimensions are associated with more severe cannabis outcomes in college students |
| Q48401484 | Children's attitudes and behavioural intentions towards a peer with symptoms of ADHD: does the addition of a diagnostic label make a difference? |
| Q43159251 | Chordoid glioma |
| Q34093252 | Chronic methylphenidate treatment during early life is associated with greater ethanol intake in socially isolated rats |
| Q91866176 | Clinical Characteristics of Women with ADHD in Japan |
| Q33778156 | Clinical use of rating scales in diagnosis and treatment of attention-deficit/hyperactivity disorder |
| Q33919558 | Co-occurring Attention Deficit Hyperactivity Disorder symptoms in adults affected by heroin dependence: Patients characteristics and treatment needs |
| Q52315942 | Co-occurring Mental Disorders in Substance Abuse Treatment: the Current Health Care Situation in Germany. |
| Q37965451 | Cognitive control and the dopamine D₂-like receptor: a dimensional understanding of addiction |
| Q46976616 | Cognitive function and nigrostriatal markers in abstinent methamphetamine abusers |
| Q44556597 | Comorbidities and costs of adult patients diagnosed with attention-deficit hyperactivity disorder |
| Q38258102 | Comorbidities in adult attention-deficit/hyperactivity disorder: a practical guide to diagnosis in primary care |
| Q40029943 | Comorbidity of Adult ADHD and Its Subtypes With Substance Use Disorder in a Large Population-Based Epidemiological Study |
| Q47184759 | Comorbidity of Internet use disorder and attention deficit hyperactivity disorder: Two adult case-control studies. |
| Q37169714 | Correlates of alcohol use in adults with ADHD and comorbid alcohol use disorders: exploratory analysis of a placebo-controlled trial of atomoxetine |
| Q36867824 | Correlates of co-occurring ADHD in drug-dependent subjects: prevalence and features of substance dependence and psychiatric disorders |
| Q37856987 | Developmental comorbidity in attention-deficit/hyperactivity disorder |
| Q37965276 | Diagnosing adult attention-deficit hyperactivity disorder: the importance of establishing daily life contexts for symptoms and impairments. |
| Q36919939 | Diagnosing and treating attention-deficit/hyperactivity disorder in adults |
| Q59594639 | Diagnóstico del trastorno por déficit de atención e hiperactividad (TDAH) en pacientes adultos con dependencia de cocaína: utilidad de los nuevos síntomas de funcionamiento ejecutivo de Barkley |
| Q38002290 | Distinguishing comorbidity and successful management of adult ADHD. |
| Q35014066 | Does ADHD predict substance-use disorders? A 10-year follow-up study of young adults with ADHD. |
| Q51991799 | Does attention-deficit hyperactivity disorder impact the developmental course of drug and alcohol abuse and dependence? |
| Q25256823 | Dose-response characteristics of methylphenidate on locomotor behavior and on sensory evoked potentials recorded from the VTA, NAc, and PFC in freely behaving rats |
| Q43526946 | Driving anger and driving behavior in adults with ADHD. |
| Q51046127 | Driving anger and other driving-related behaviors in high and low ADHD symptom college students. |
| Q35580455 | Drug Therapy for Adults with Attention-Deficit Hyperactivity Disorder |
| Q36802144 | Duplications in ADHD patients harbour neurobehavioural genes that are co-expressed with genes associated with hyperactivity in the mouse |
| Q24657705 | EEG biofeedback as a treatment for substance use disorders: review, rating of efficacy, and recommendations for further research |
| Q37040028 | Early exposure to stimulant medications and substance-related problems: The role of medical and nonmedical contexts. |
| Q37385158 | Effect of prior stimulant treatment for attention-deficit/hyperactivity disorder on subsequent risk for cigarette smoking and alcohol and drug use disorders in adolescents |
| Q92854981 | Effects of Exercise on Cognitive Performance in Children and Adolescents with ADHD: Potential Mechanisms and Evidence-based Recommendations |
| Q102054046 | Effects of substance misuse on reward-processing in patients with attention-deficit/hyperactivity disorder |
| Q37010436 | Efficacy of central nervous system stimulant treatment for cocaine dependence: a systematic review and meta-analysis of randomized controlled clinical trials |
| Q57399827 | Epidemiology of Attention Deficit Hyperactivity Disorder |
| Q40207289 | Expert Opinion and Recommendations for the Management of Attention-Deficit/Hyperactivity Disorder in Correctional Facilities. |
| Q35685121 | Extended-Release Mixed Amphetamine Salts vs Placebo for Comorbid Adult Attention-Deficit/Hyperactivity Disorder and Cocaine Use Disorder: A Randomized Clinical Trial |
| Q36701753 | Externalizing disorders in the offspring from the San Diego prospective study of alcoholism |
| Q57400210 | Family based association analysis of statistically derived quantitative traits for drug use in ADHD and the dopamine transporter gene |
| Q33780090 | From the black widow spider to human behavior: Latrophilins, a relatively unknown class of G protein-coupled receptors, are implicated in psychiatric disorders |
| Q35950888 | Gene-environment interplay in alcoholism and other substance abuse disorders: expressions of heritability and factors influencing vulnerability |
| Q42668136 | Genetic and environmental influences on the relationship between adult ADHD symptoms and self-reported problem drinking in 6024 Dutch twins |
| Q37479840 | Genetic and non-genetic influences on the development of co-occurring alcohol problem use and internalizing symptomatology in adolescence: a review |
| Q82157402 | Genetic risks and ADHD symptomatology: exploring the effects of parental antisocial behaviors in an adoption-based study |
| Q38740139 | Guidelines of the Brazilian Association of Studies on Alcohol and Other Drugs (ABEAD) for diagnosis and treatment of psychiatric comorbidity with alcohol and other substance and dependence. |
| Q41281871 | Heavy Drinking in University Students With and Without Attention-Deficit/Hyperactivity Disorder: Contributions of Drinking Motives and Protective Behavioral Strategies. |
| Q60491954 | History of childhood attention deficit hyperactivity disorder (ADHD) features among adults with panic disorder |
| Q48439365 | Hyperactivity and attention problems in a Swiss sample of school-aged children: effects of school achievement, child gender, and informants |
| Q74450668 | Hyperactivity and its primary disorders in the childhood population |
| Q33938089 | Impact of substance abuse on the course and treatment of bipolar disorder |
| Q34576973 | Influence of ethanol and gender on methylphenidate pharmacokinetics and pharmacodynamics |
| Q37381307 | Interoception and drug addiction |
| Q55404796 | Is Cannabis Use Associated With the Worst Inpatient Outcomes in Attention Deficit Hyperactivity Disorder Adolescents? |
| Q37557589 | Issues in the management of patients with complex attention-deficit hyperactivity disorder symptoms |
| Q34763735 | Lisdexamfetamine dimesylate for the treatment of attention deficit hyperactivity disorder in adults with a history of depression or history of substance use disorder. |
| Q37318744 | Management of attention-deficit hyperactivity disorder in adults: focus on methylphenidate hydrochloride |
| Q37341477 | Marijuana use is associated with inattention in men and sleep quality in women with Attention-Deficit/Hyperactivity Disorder: a preliminary study |
| Q35568469 | Medical use, illicit use and diversion of prescription stimulant medication |
| Q37960505 | Methylphenidate transdermal system: clinical applications for attention-deficit/hyperactivity disorder |
| Q43182271 | Methylphenidate. Therapy option for adults with ADHD and comorbid substance use disorder? |
| Q37114232 | Neurocognitive and psychiatric dimensions of hot, but not cool, impulsivity predict HIV sexual risk behaviors among drug users in protracted abstinence |
| Q31155590 | Neuroimaging the neural correlates of increased risk for substance use disorders in attention-deficit/hyperactivity disorder-A systematic review |
| Q36911401 | Neuropsychiatric effects of prescription drug abuse |
| Q80238362 | New developments in the treatment of attention-deficit/hyperactivity disorder in primary care |
| Q46576630 | New drugs for treatment of attention-deficit/hyperactivity disorder |
| Q34468658 | New methylphenidate formulations for the treatment of attention-deficit/hyperactivity disorder |
| Q51899876 | Nicotine and alcohol dependence in patients with comorbid attention-deficit/hyperactivity disorder (ADHD). |
| Q26774425 | Optimal management of ADHD in older adults |
| Q94011588 | Pathological Gambling and Alcohol Use Disorder |
| Q37103667 | Pharmacologic treatment of ADHD: road conditions in driving patients to successful outcomes |
| Q38065287 | Pharmacological and clinical dilemmas of prescribing in co-morbid adult attention-deficit/hyperactivity disorder and addiction |
| Q81020354 | Pharmacological treatment in adults with attention deficit hyperactivity disorder |
| Q39610434 | Pharmacotherapy for parents with attention-deficit hyperactivity disorder (ADHD): impact on maternal ADHD and parenting |
| Q28138163 | Pharmacotherapy of adolescent attention deficit hyperactivity disorder: challenges, choices and caveats |
| Q46230384 | Polymorphisms TaqI A of the DRD2, BalI of the DRD3, exon III repeat of the DRD4, and 3' UTR VNTR of the DAT: association with childhood ADHD in male African-Caribbean cocaine dependents? |
| Q37627943 | Practitioner review: Non-pharmacological treatments for ADHD: a lifespan approach |
| Q34194717 | Prediction of ADHD to anxiety disorders: an 11-year national insurance data analysis in Taiwan |
| Q33778198 | Predictors of long-term outcome in children with attention-deficit/hyperactivity disorder |
| Q35223506 | Prevalence and correlates of attention-deficit hyperactivity disorder symptoms in Korean college students |
| Q77462295 | Prevalence of adult attention-deficit hyperactivity disorder among cocaine abusers seeking treatment |
| Q44973697 | Prevalence of comorbid substance use disorder during long-term central stimulant treatment in adult ADHD. |
| Q37001184 | Prospective relationships of ADHD symptoms with developing substance use in a population-derived sample |
| Q39216392 | Psychiatric Comorbidities in a New Zealand Sample of Adults With ADHD. |
| Q51898903 | Psychiatric comorbidity and functional impairment in a clinically referred sample of adults with attention-deficit/hyperactivity disorder (ADHD). |
| Q36594945 | Psychiatric comorbidity in adults with attention-deficit/hyperactivity disorder (ADHD). |
| Q36026845 | Remission in children and adolescents diagnosed with attention-deficit/hyperactivity disorder via an effective and tolerable titration scheme for osmotic release oral system methylphenidate |
| Q46186036 | Retrospective evaluation of attention deficit hyperactivity disorder with the Wender Utah Rating Scale in a sample of Spanish prison inmates |
| Q89166759 | Reward-Based Learning as a Function of Severity of Substance Abuse Risk in Drug-Naïve Youth with ADHD |
| Q58781406 | Serial Progression from Attention-Deficit/Hyperactivity Disorder to Alcohol Use Disorder: Serial Multiple Mediated Effects of Externalizing Disorders and Depression |
| Q42365168 | Skills and compensation strategies in adult ADHD - A qualitative study |
| Q48447777 | Specificity of quantitative EEG analysis in adults with attention deficit hyperactivity disorder |
| Q36785633 | Substance abuse and personality disorder comorbidity in adolescent outpatients: are girls more severely ill than boys? |
| Q36227906 | Substance abuse in patients with attention-deficit hyperactivity disorder : therapeutic implications |
| Q37103681 | Substance abuse in patients with attention-deficit/hyperactivity disorder. |
| Q43862039 | Substance use disorder and ADHD: is ADHD a particularly "specific" risk factor? |
| Q36992381 | Symptom dimensions of attention deficit hyperactivity disorder and nicotine withdrawal symptoms |
| Q44101806 | Symptom prevalence of ADHD in a community residential substance abuse treatment program |
| Q43963201 | Temporal association between childhood psychopathology and substance use disorders: findings from a sample of adults with opioid or alcohol dependency |
| Q33857056 | The International ADHD in Substance Use Disorders Prevalence (IASP) study: background, methods and study population. |
| Q37750668 | The association between psychopathology and substance use in young people: a review of the literature |
| Q44297593 | The association of preceding traumatic brain injury with mental disorders, alcoholism and criminality: the Northern Finland 1966 Birth Cohort Study |
| Q38023225 | The negative impact of attention-deficit/hyperactivity disorder on occupational health in adults and adolescents |
| Q34673021 | The use of stimulants and atomoxetine in adults with comorbid ADHD and bipolar disorder. |
| Q84269285 | Toward a new understanding of attention-deficit hyperactivity disorder: advances in research and treatment |
| Q46655617 | Tracking Distraction |
| Q59330198 | Trait Anxiety as a Mediator of the Association between Attention Deficit Hyperactivity Disorder Symptom Severity and Functional Impairment |
| Q33859840 | Trajectories of Substance Use Disorders in Youth: Identifying and Predicting Group Memberships |
| Q36338808 | Treatments for Adolescents With Comorbid ADHD and Substance Use Disorder: A Systematic Review |
| Q37682858 | Trend, characteristics, and pharmacotherapy of adults diagnosed with attention-deficit/hyperactivity disorder: a nationwide survey in Taiwan |
| Q44403562 | Untreated ADHD in adults: are there sex differences in symptoms, comorbidity, and impairment? |
| Q51921246 | Validity of self-report and informant rating scales of adult ADHD symptoms in comparison with a semistructured diagnostic interview. |
| Q36960189 | When ADHD and substance use disorders intersect: relationship and treatment implications |
Search more.